1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3 Kemurnian >98,0% (HPLC) Brexpiprazole Intermediate Factory
Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]tiofen CAS 5118-13-8
1-(1-Benzothiophen-4-yl) piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-siji CAS 913613-82-8
4-Chlorobenzo[b]tiofen CAS 66490-33-3
Jeneng Kimia | 1-(1-Benzothiophen-4-yl) piperazine Hydrochloride |
sinonim | Brexpiprazole Intermediate 2;1-Benzo[b]thien-4-yl-Piperazine Hydrochloride;1-Benzo[b]thien-4-ylpiperazine Monohydrochloride |
Nomer CAS | 913614-18-3 |
Nomer CAT | RF-PI1034 |
Status Simpenan | Ing Simpenan, Kapasitas Produksi 100MT / Taun |
Formula Molekul | C12H15ClN2S |
Bobot Molekul | 254.7789 |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Bubuk Putih nganti Putih |
Identifikasi | Wektu retensi sampel cocog karo standar referensi |
Kemurnian / Metode Analisis | > 99,0% (HPLC) |
Mundhut ing Pangatusan | <0,50% |
Banyu (KF) | <0,50% |
Sisa ing Ignition | <0,20% |
Zat sing gegandhengan | (HPLC) |
Sembarang Najis Individu | <0,50% |
Total Impurities | <1.00% |
Spektrum Infra Merah | Conforms kanggo Struktur |
Proton NMR Spectrum | Conforms kanggo Struktur |
Standar Tes | Standar Perusahaan |
Panggunaan | Intermediate saka Brexpiprazole (CAS: 913611-97-9) |
Paket: Botol, tas Aluminium foil, 25kg / Drum Karton, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride (CAS: 913614-18-3) minangka perantara saka Brexpiprazole (CAS: 913611-97-9).Brexpiprazole minangka jinis antipsikotik atipikal.Iki minangka agonis parsial reseptor dopamin D2.Minangka modulator aktivitas serotonin-dopamin novel, bisa digunakake kanggo perawatan skizofrenia, lan kanggo perawatan tambahan kanggo depresi.Uga bisa nyedhiyakake khasiat lan toleransi kanggo perawatan tambahan sing wis ditemtokake kanggo kelainan depresif mayor (MDD).Obat kasebut nuduhake profil farmakologis sing unik, tumindak minangka agonis parsial saka reseptor serotonin 5-HT1A lan dopamin D2 lan minangka antagonis lengkap reseptor 5-HT2A lan noradrenalin α1B / 2C, kanthi afinitas ikatan subnanomolar sing padha.Obat kasebut, sing dikembangake dening Otsuka lan Lundbeck, disetujoni ing 2015 dening FDA kanggo perawatan skizofrenia lan minangka perawatan tambahan kanggo depresi.